Canadian Healthcare Resource Use and Costs for Relapsed/Refractory Lymphoma Treatments

Supplementary data for the article 'Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma – Canadian perspective' published in the Journal of Comparative Effectiveness Research. The dataset contains 24 tables detailing drug costs, resource use, adverse events, and productivity impacts from Canadian and Quebec perspectives. Kimberly Guinan authored this 212.8 KB document, last updated on 2026-04-20.

Use Cases

• Modeling the economic impact of subcutaneous vs. intravenous therapies based on chair time and healthcare professional time data.
• Comparing treatment costs across Canadian provinces using the separate Canadian and Quebec perspective tables.
• Estimating the cost burden of adverse events like Cytokine Release Syndrome using the provided frequency and cost inputs.
• Analyzing productivity loss for patients and caregivers based on the impairment tables.

Strengths

• Contains 24 structured tables covering multiple facets of healthcare resource use and cost analysis.
• Provides separate data perspectives for Canada and Quebec, allowing for regional comparisons.
• Includes data on specific adverse events, professional fees, and productivity impairment, which are detailed in the table list.

Limitations

• Row counts and specific column definitions are unknown, requiring manual inspection after download.
• The dataset is small at 212.8 KB, indicating a limited scope focused on model inputs rather than large-scale patient records.
• Documentation is limited to table titles; field semantics must be inferred from the accompanying article.

Provenance

Source

figshare, as supplementary material for a peer-reviewed journal article.

Collection Method

Likely derived from clinical trial data, healthcare system records, and expert input for a health economic model.

Freshness

Last updated 2026-04-20 10:29:16.

Geography

Canada, with a specific focus on Quebec.